AD Target / Therapy Types
The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.
|Target Types||Timeline||Phase 1||Phase 2||Phase 2/3||Phase 3||Phase 4||Approved||Inactive||Discontinued||Total|
|APP and Amyloid-Related||View Timeline||3||11||2||3||0||0||3||11||33|
|Other Neurotransmitter Systems||0||4||0||2||0||1||2||10||19|
|Therapy Types||Timeline||Phase 1||Phase 2||Phase 2/3||Phase 3||Phase 4||Approved||Inactive||Discontinued||Total|
|Immunotherapy (active)||View Timeline||0||2||0||0||0||0||0||2||4|
|Immunotherapy (passive)||View Timeline||2||3||1||2||0||0||0||3||11|
- PBT2 Takes a Dive in Phase 2 Alzheimer’s Trial
- Coenzyme Q10 Strikes Out in Phase 3 for Parkinson’s
- BACE Inhibitor Heads for Phase 2/3 Trials
- Citalopram Calms Agitation in Alzheimer’s, but Carries Risks
- Resolving Controversies on the Path to AD Therapeutics
- Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD
- Of Mice and Men: Bridging the Translational Disconnect in CNS Drug Discovery
- Can We (Should We?) Develop “Smart Drugs” to Stave Off Age-Related Memory Loss?
ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.
Patient Resources page is a collection of web sites that can provide assistance and support for Alzheimer patients, their families and caregivers.